Serum Levels of Prostate Specific Antigen and Specific Reproductive Hormones Among Male Subjects with Benign Prostate Hyperplasia in Port Harcourt, Nigeria
Article Sidebar
Main Article Content
Abstract
Benign prostate hyperplasia (BPH) is a medical condition in elderly men in which there is proliferation and enlargement of the prostate gland. This study evaluated the levels of male reproductive hormones among subjects with BPH. The study involved 150 subjects aged 40 years and above, comprising 80 BPH subjects attending the urology clinic and 70 control subjects. Five millilitres (5ml) of venous blood were collected from each subject into plain bottles for the determination of prostate-specific antigen (PSA), testosterone, prolactin, and estradiol, using the ELISA technique. The mean values of PSA (16.68±10.96 ng/ml), estradiol (71.03±18.56 pg/ml) and for the BPH subjects and prolactin (9.38±4.51 ng/ml) were significantly higher compared to the mean values of PSA (0.48±0.25ng/ml), estradiol (51.33±7.13npg/ml) and prolactin (6.92±1.93ng/ml) of the control subjects. However, the mean testosterone value of the BPH subjects (5.02±1.93 ng/ml) was significantly lower than the mean value for the control (6.57±3.48ng/ml). The BPH who used to consume alcohol had higher PSA (24.26±8.33ng/ml) and testosterone (7.68±3.41ng/ml) compared to the PSA (16.34±3.22ng/ml) and testosterone (4.95±3.62ng/ml) of those who never consumed alcohol. The BPH had significantly altered hormone parameters as well as raised PSA levels. Including hormonal parameters in diagnosing and managing BPH could be an important consideration in our population.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Song JH, Hwang B, Chung HJ, Moon B, Kim JW, Ko K, Kim BW, Kim WR, Kim WJ, Myung SC, Moon SK. Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Inhibits Benign Prostatic Hyperplasia In Vitro and In Vivo. World Journal of Men’s Health. 2020; 38(3):385-396.
Nemr E, El Helou E, Mjaess G, Semaan A, Chebel J A. Prospective Multicenter Open-Label One-Arm Trial Investigating a Pumpkin Seed, Isoflavonoids, and Cranberry Mix in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: A Pilot Study. Advances in Urology. 2020; 6325490.
Ajayi A, Abraham K. Understanding the role of estrogen in the development of benign prostate hyperplasia. African Journal of Urology. 2018; 24(2): 93-97
Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011; 82(4-5): 184–199.
Zaruwa MZ, Muhammad YB, Abdullahi HS, Ubana MA, Ubaoji KI, Adamu RM. Evaluation of Diclofenac (DCF) Potassium as a Possible Predisposer of Benign Prostatic Hyperplasia in Wistar Albino Rats. Saudi Journal of Biomedical Research. 2020; 58: 243-248
McCormick BJ, Raynor MC. The Prostate and Benign Prostatic Hyperplasia Prostatic Artery Embolization. 2020. (pp. 1-9): Springer.
Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we know? BJU International. 2020; 127 (4): 389-399
Roehrborn CG. Pathology of benign prostatic hyperplasia. International Journal of Impotence Research. 2008; 20 Suppl 3:S11-18
McPherson SJ, Hussain S, Balanathan P., Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A. 2010; 107(7):3123-8.
Madersbacher S, Sampson S, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019; 65 (5): 458–464.
Roueta V, Bogorada RL, Kaysera C, Kessala K, Genestiec C, Bardierc A, Grattand DR, Keldere B, Kopchicke JJ, Kelly PA, Goffin V. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. PNAS. 2010; 107 (34): 15199–15204
Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urology. 2012; 8(11):597-607
Karen SS, Angelo MD. Prostate cancer and inflammation: the evidence. Histopathology. 2012; 60:199-215.
Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM, Goodman PJ, Thompson IM, Lippman SM, Lucia MS, Parnes HL, Drake CG, Nelson WG, De Marzo AM, Platz EA. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer. Prostate Cancer and Prostatic Disease. 2015; 18(3): 264-9.
Kapoor A. Benign prostate hyperplasia (BPH) management in the primary care setting. The Canadian Journal of Urology. 2012; 19(Suppl 1): 10-17.
Adejumo B, Williams O, Odigie E, Unachukwu I, Abdulrahman O, Dimkpa U, Uzor S, Adebowale O, Oke O. Serum Levels of Reproductive Hormones and Their Relationship with Age in Men with Benign Prostatic Hyperplasia in Benin City, Edo State. Health. 2020; 12: 1121-1131
Khaleel FM, Al-Shammri IA, Mohammed NA. Estimation of Testosterone, Estradiol and some Markers inSera of Iraqi Patients with Benign Prostatic Hyperplasia. Baghdad Science Journal. 2013; 10(4): 1162-1171
Duarsa GWK, Sari YA, Oka AAG, Santosa KB, Yudiana IW, Tirtayasa PPM, Pramana IBP, Kloping YP. Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia pa-tients. Asian Journal of Urology. 2021; 8(3):289-297
Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002; 5:98–102
Marchetti PM, Barth JH. Clinical biochemistry of dihydrotestosterone. Annals of Clinical Biochemistry. 2013; 50(2): 95-107.
Khalil R, King MA, Soliman MRI. Testosterone reverses ethanol-induced deficit in spatial reference memory in castrated rats. Pharmacology. 2005; 75:87–92.
Zheng C, Luo Y, Chen Y, Chen D, Shao C, Huang D, Zhu J, Mao X, Li L, Sun Z. Oral exposure of sulpiride promotes the proliferation of Brown Norway rat prostates. Experimental And Therapeutic Medicine. 2020; 19: 2551-2562.
Vignera SL, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016; 4(3): 404-411
Sayeed QA, Khatoon F, Bahmed F, Kaleem M. Effect of Testosterone and Estrogen Ratio - An indicator of Benign Prostatic Hyperplasia (BPH). Indian Journal of Clinical Anatomy and Physiology. 2016; 3(2): 125-130
Mathur RP, Nayak S, Sivaramakrishnan R, Jain V. Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia. Journal of the Association of Physicians of India. 2014; 62: 40-44.
Li H, Xu T-Y, Li Y, Chia YC, Buranakitjaroen P, Cheng HM, Huynh MV, Sogunuru GP, Tay JC, Waang TD, Kario L, Wang JG. Role of α1-blockers in the current management of hypertension. Journal of Clinical Hypertension. 2022; 24: 1180–1186.
Escandriolo NJD, Colla RH, Ravazzani GR, Gaido MI, Bertolotto P, Actis AB. Prostate-specific antigen: its relationship with alcohol intake and tobacco. Med Oncology. 2012; 29(2):823–826
Rao M, Zuo L.-D, Fang F, Martin K., Zheng Y, Zhang H.-P, Li H.-G, Zhu C.-H, Xiong C.-L, Guan H.-T. Association of Alcohol Consumption with Markers of Prostate Health and Reproductive Hormone Profiles: A Multi-Center Study of 4535 Men in China. PLoS ONE. 2015; 10: e0142780
Bradley CS, Erickson BA, Messersmith EE, Lai HH, Kreder KJ, Yang CC, Merion RM, Bavendam TG, Kirkali Z. Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review. Urology. 2017; 198(5): 1010-1020
Elrifai A, Kotb AF, Sharaki O, Abdelhady M. Correlation of body mass index with serum total PSA, total testosterone and prostatic volume in a sample of men. Polish Annals of Medicine. 2016; 23(1):1-5.
Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and Benign Prostatic Hyperplasia: Clinical Connections, Emerging Etio-logical Paradigms and Future Directions. The Journal of Urology. 2013; 189(1S): S102-S106.
Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, Higgins B, Lynch S, Rozanski T, Troyer D, Thompson I. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005; 103:1092–1095.
Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008; 71:787–791.